Oncology
CLL Just Moved a Noncovalent BTK Inhibitor Into First Line
FDA has approved pirtobrutinib for previously untreated CLL or SLL without known 17p deletion. The approval pushes a noncovalent BTK inhibitor into first-line care after a Phase III trial produced a striking progression-free survival advantage over chemoimmunotherapy.
HER2-Mutant Lung Cancer Just Moved Into First Line
Cancer Screening Is Still Designed for the Able-Bodied Patient
Breast Cancer Just Proved Why Biomarker Selection Matters
Brain Cancer Finally Gets the PET Scan It Has Been Missing
The Thymus May Be the Organ Radiation Oncology Forgot
The mRNA Cancer Vaccine Story Just Got Less Comfortable
RAS Has Finally Hit Pancreatic Cancer. Now Access Has to Catch Up.
Polycythemia Vera Gets a First-in-Class Option. Patients Need More Than Blood Draws.
HER2 Testing Just Became the Gatekeeper in Gastroesophageal Cancer
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
Diseases in Oncology
Explore disease data and country profiles on the IPM Alliance platform.
Explore diseases